Frontiers in molecular biosciences · 2026
Exploring the role of adenosine deaminase in esophageal cancer and its potential for traditional Chinese medicine intervention.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tian Xiaoling, Liu Yanhong, Wang Baochun, Liu Yubo, Liu Fengqi, Wang Chenlin, Lv Shuang, Hua Yunqi, Yin Fangrui
Аннотация
INTRODUCTION: This study aims to systematically elucidate the association of adenosine deaminase with esophageal cancer from a genetic perspective and explore its potential underlying mechanisms and intervention strategies.
METHODS: Through multi-level integrative analysis, two-sample Mendelian randomization analysis was performed, followed by serum validation in an independent case-control cohort. Transcriptomic analysis, co-expression network enrichment, single-cell RNA sequencing, reverse network pharmacology screening, and molecular docking simulation were conducted.
RESULTS: Mendelian randomization identified adenosine deaminase as a potential risk factor for esophageal cancer (OR = 1.23, 95% CI: 1.00-1.52). Significantly elevated serum ADA levels were validated in patients. ADA expression was upregulated in tumor tissues, and its co-expression network was significantly enriched in pathways related to "proteasome" and "protein folding." Single-cell analysis showed high ADA expression primarily in plasma cells and plasmacytoid dendritic cells. Two potential lead compounds, catechin and flavoxanthin, were identified to stably bind to ADA.
DISCUSSION: Collectively, these findings suggest a potential role for ADA in the occurrence of esophageal cancer and highlight its possible relevance as a therapeutic target, providing new directions for early intervention and targeted therapy of esophageal cancer.
METHODS: Through multi-level integrative analysis, two-sample Mendelian randomization analysis was performed, followed by serum validation in an independent case-control cohort. Transcriptomic analysis, co-expression network enrichment, single-cell RNA sequencing, reverse network pharmacology screening, and molecular docking simulation were conducted.
RESULTS: Mendelian randomization identified adenosine deaminase as a potential risk factor for esophageal cancer (OR = 1.23, 95% CI: 1.00-1.52). Significantly elevated serum ADA levels were validated in patients. ADA expression was upregulated in tumor tissues, and its co-expression network was significantly enriched in pathways related to "proteasome" and "protein folding." Single-cell analysis showed high ADA expression primarily in plasma cells and plasmacytoid dendritic cells. Two potential lead compounds, catechin and flavoxanthin, were identified to stably bind to ADA.
DISCUSSION: Collectively, these findings suggest a potential role for ADA in the occurrence of esophageal cancer and highlight its possible relevance as a therapeutic target, providing new directions for early intervention and targeted therapy of esophageal cancer.